Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
August 13, 2010
Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
Vermillion said that 1,247 OVA1 tests were performed during the quarter, and it recognized revenue for 342 of them. The company expects to sell between 8,000 and 10,000 OVA1 tests total in 2010, and believes there is an opportunity to eventually sell more than 1 million tests per year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor - Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011 / ProteoMonitor - Vermillion Planning Layoffs, Seeking New Partnerships in 2012
January 6, 2012 / ProteoMonitor - Vermillion Plans to Raise Up to $17.3M in Stock Offering
January 21, 2011 / ProteoMonitor